Divergent Views Of Patent Eligibility Give Little Insight

Law360, New York (November 13, 2012, 5:48 PM EST) -- In a very important decision for the biotechnology industry, the Court of Appeals for the Federal Circuit recently reaffirmed its holding that patent claims directed to isolated genes and a method that uses the genes to screen for breast cancer risk are patent eligible.

In contrast, claims directed to methods of analyzing or comparing a patient’s sequence of a BRCA1 gene or BRCA1 RNA with a wild-type sequence to reveal cancer-predisposing mutations are patent ineligible (see Assn. for Molecular Pathology v. U.S. Patent and Trademark Office...
To view the full article, register now.